Treatment of metabolic disorders in feline animals

Patent metadata

Field	Value
Publication number	US-10617666-B2
Application number	US-201414573352-A
Country	US
Kind code	B2
Filing date	Dec 17, 2014
Priority date	Dec 17, 2013
Publication date	Apr 14, 2020
Grant date	Apr 14, 2020

Abstract

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

First claim

The invention claimed is:

1. A method of treatment or prevention of a metabolic disorder in a feline animal comprising administering to the feline animal a composition that comprises an SGLT2 inhibitor or pharmaceutically acceptable form thereof, wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof consists of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, represented by the following formula:

wherein:
the metabolic disorder is selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1, diabetes mellitus type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function, diabetic remission, and combinations thereof; and

said SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered at a dose from 0.1 to 1 mg/kg body mass per day.

2. The method according to claim 1 , wherein the metabolic disorder is selected from the group consisting of pre-diabetes, diabetes mellitus type 1, diabetes mellitus type 2, and clinical conditions associated with pre-diabetes, diabetes mellitus type 1 or diabetes mellitus type 2.

3. The method according to claim 2 , wherein said metabolic disorder is pre-diabetes, diabetes mellitus type 2 or a clinical condition associated with pre-diabetes or diabetes mellitus type 2.

4. The method according to claim 2 , wherein said clinical condition is a condition selected from the group consisting of ketoacidosis, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function, diabetic remission, and combinations thereof.

5. The method according to claim 1 , wherein said ketoacidosis, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome), of pancreatic beta cell function and/or diabetic remission is associated with diabetes.

6. The method according to claim 5 , wherein said diabetes is pre-diabetes or diabetes mellitus type 2.

7. The method according to claim 1 , wherein the feline animal is obese.

8. The method according to claim 1 , wherein the feline animal is suffering from diabetes.

9. The method according to claim 8 , wherein said diabetes is pre-diabetes or diabetes mellitus type 2.

10. The method according to claim 1 , wherein the feline animal is a cat.

11. The method according to claim 1 , wherein said inhibitor or pharmaceutically acceptable form thereof is administered only once per day.

12. The method according to claim 1 , further comprising administering to the feline animal a combination of insulin and the SGLT2 inhibitor or pharmaceutically acceptable form thereof.

13. The method according to claim 12 , wherein the composition comprises a 1:1 crystalline complex of the SGLT2 inhibitor or pharmaceutically acceptable form thereof and an amino acid, and the crystalline complex is a crystalline hydrate.

14. The method according to claim 13 , wherein said amino acid comprises proline.

15. The method according to claim 14 , wherein said amino acid comprises L-proline.

16. A method of treatment or prevention of a metabolic disorder in a feline animal comprising administering to the feline animal a composition that comprises an SGLT2 inhibitor or pharmaceutically acceptable form thereof at a dose from 0.01 to 5.0 mg/kg body mass per day, wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof consists of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, represented by the following formula:

wherein:
the metabolic disorder is selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1, diabetes mellitus type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function, diabetic remission, and combinations thereof; and

the composition comprises a 1:1:1 crystalline complex of the SGLT2 inhibitor or pharmaceutically acceptable form thereof, L-proline and water in a crystalline form.

17. The method according to claim 16 , wherein the 1:1:1 crystalline complex is characterized by an X-ray powder diffraction pattern that comprises peaks at 20.28, 21.14 and 21.64 degrees 2⊖ (±0.1 degrees 2⊖), wherein said X-ray powder diffraction pattern is made using CuK α1 radiation.

18. A method of treatment or prevention of a metabolic disorder in a feline animal comprising administering to the feline animal a composition that comprises an SGLT2 inhibitor or pharmaceutically acceptable form thereof at a dose from 0.01 to 5.0 mg/kg body mass per day, wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof consists of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, represented by the following formula:

wherein:
the metabolic disorder is selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1, diabetes mellitus type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy, Syndrome X (metabolic syndrome), loss of pancreatic beta cell function, diabetic remission, and combinations thereof; and

the composition comprises a 1:1 crystalline complex of the SGLT2 inhibitor or pharmaceutically acceptable form thereof and an amino acid, and the crystalline complex is a crystalline hydrate.

Assignees

• Boehringer Ingelheim Vetmedica Gmbh

Inventors

• Reiche Dania Birte
• Haag-Diergarten Silke
• Hennings Leah Jeanette
• Kley Saskia
• Traas Anne M

Classifications

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61K38/28

  Insulins · CPC title

• A61K31/357

  having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K31/7042

  Compounds having saccharide radicals and heterocyclic rings · CPC title